P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Crohn's and Colitis Année : 2022

P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?

(1, 2) , (3, 4, 5) , , (6) , (7) , (4, 3, 5) , , (1, 8) , (9) , (9)
1
2
3
4
5
6
7
8
9
Fichier non déposé

Dates et versions

hal-03665864 , version 1 (12-05-2022)

Identifiants

  • HAL Id : hal-03665864 , version 1

Citer

Mathurin Fumery, S. Nancey, J. Filippi, R. Altwegg, X. Hebuterne, et al.. P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?. Journal of Crohn's and Colitis, 2022, 16 (1), pp.I439. ⟨hal-03665864⟩
23 Consultations
0 Téléchargements

Partager

Gmail Facebook Twitter LinkedIn More